Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Brief Summary: This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.


Options:
A: Arm Label: Arm 1 (Control Arm); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm 2 (Research arm); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm 3 (Research arm); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Research arm) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm 3 (Research arm) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm 1 (Control Arm) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm 2 (Research arm), Arm 3 (Research arm)
B: Arm Label: Participants receiving Niraparib; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Participants receiving Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Participants receiving Niraparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Participants receiving Placebo
C: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)
D: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily

Answer: B